A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective...

Area of Science:

• Immunology
• Oncology
• Carbohydrate Chemistry

Background:

• Tumor-associated carbohydrate antigens (TACAs) are crucial targets for cancer vaccines.
• Native TACAs like α-Tn show promise but suffer from poor immunogenicity, in vivo instability, and low bioavailability, hindering clinical translation.
• Development of improved vaccine strategies is essential for effective cancer immunotherapy.

Purpose of the Study:

• To develop and evaluate a novel cancer vaccine prototype based on Tn-antigen mimetics.
• To assess the safety, immunogenicity, and efficacy of the new vaccine in preclinical models.

Main Methods:

• Conjugation of four clustered Tn-antigen mimetics and an immunogenic peptide epitope to a cyclopeptide carrier.
• Immunization of mice with the novel vaccine prototype.
• Assessment of antibody responses (IgM, IgG1, IgG2a, IgG3) and tumor regression via antibody-dependent mechanisms.

Main Results:

• The vaccine prototype was found to be safe upon immunization.
• Strong and long-lasting Tn-specific immune responses were induced, including IgM and IgG antibodies capable of recognizing native carbohydrate antigens.
• High titers of IgG1, IgG2a, and IgG3 antibodies were produced.
• Significant antibody-dependent tumor regression and protection were observed.

Conclusions:

• The developed vaccine prototype is safe and elicits a potent, durable immune response against Tn-expressing cancer targets.
• The findings support the clinical development of this novel vaccine for treating cancers expressing Tn antigens.
• This strategy offers a promising therapeutic approach for cancer immunotherapy.